Posts

Posted on

INVESTOR ALERT: Compass Diversified Holdings Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit – CODI

PR Newswire


SAN DIEGO
, June 21, 2025 /PRNewswire/ — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Compass Diversified Holdings (NYSE: CODI) publicly traded securities between May 1, 2024 and May 7, 2025, all dates inclusive (the “Class Period”), have until Tuesday, July 8, 2025 to seek appointment as lead plaintiff of the Compass Diversified class action lawsuit. Captioned Augenbaum v. Compass Diversified Holdings, No. 25-cv-01003 (C.D. Cal.), the Compass Diversified class action lawsuit charges Compass Diversified Holdings, Compass Group Diversified Holdings LLC, Compass Group Management LLC, as well as certain of Compass Diversified’s current and former executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Compass Diversified class action lawsuit, please provide your information here:


https://www.rgrdlaw.com/cases-compass-diversified-holdings-class-action-lawsuit-codi.html
 

You can also contact attorneys

J.C. Sanchez

or


Jennifer N. Caringal


of Robbins Geller by calling 800/449-4900 or via e-mail at

[email protected]

.

CASE ALLEGATIONS: On September 7, 2021, Compass Diversified announced the acquisition of a majority interest in Lugano Holdings, Inc., a designer, manufacturer, and marketer of high-end jewelry, in a deal with an enterprise value of $256 million (excluding working capital and certain other adjustments upon closing).

The Compass Diversified class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Lugano had violated applicable accounting rules and acceptable industry practices with respect to its financing, accounting, and inventory practices during Compass Diversified fiscal 2024; (ii) Lugano’s 2024 financial results had been artificially distorted by these irregularities; (iii) Compass Diversified had failed to implement effective internal controls over Compass Diversified’s financial reporting; and (iv) as a result, Compass Diversified’s reported 2024 financial results did not reflect the actual financial results of Compass Diversified and such reported results were materially misstated.

On May 7, 2025 Compass Diversified issued a press release titled “Compass Diversified Discloses Non-Reliance on Financial Statements for Fiscal 2024 Amid an Ongoing Internal Investigation into its Subsidiary, Lugano Holding, Inc.” revealing that Compass Diversified “has preliminarily identified irregularities in Lugano’s non-CODI financing, accounting, and inventory practices. After discussing with senior leadership and investigators, the Audit Committee of CODI’s Board has concluded that the previously issued financial statements for 2024 require restatement and should no longer be relied upon.” Compass Diversified’s release also announced that Compass Diversified intended to delay the filing of its first quarter 2025 Form 10-Q. On this news, the price of Compass Diversified’s stock fell more than 62%.

The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Compass Diversified publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Compass Diversified class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Compass Diversified class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Compass Diversified class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Compass Diversified class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.

Contact:

Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
[email protected] 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-compass-diversified-holdings-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit—codi-302487393.html

SOURCE Robbins Geller Rudman & Dowd LLP

Posted on

The China Fund, Inc. Announces Board Approval of Plan of Liquidation

BOSTON, June 20, 2025 (GLOBE NEWSWIRE) — The China Fund, Inc. (NYSE: CHN) (the “Fund”) announced today that its Board of Directors (the “Board”) has approved a plan of liquidation and dissolution (the “Plan”) for the Fund. The Plan will be submitted to Fund stockholders for approval at a Special Meeting. The date of the Special Meeting and more detailed information about the proposed liquidation and Plan will be set forth in a proxy statement to be mailed to the Fund’s stockholders in the near future. The Board recommends that the Fund’s stockholders vote for the liquidation of the Fund at the Special Meeting.

In determining to liquidate the Fund, the Board considered a variety of factors including, among others, prevailing geopolitical and market conditions, the size of the Fund, the trading volume of the Fund’s shares, the Fund’s discount to net asset value, and the availability of competing open-end products, such as exchange-traded funds. The Board also considered alternatives, including converting the Fund into an open-end management investment company. On balance, the Board determined that the liquidation of the Fund is in the best interests of the Fund and its stockholders.

The Fund intends to file a proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) with respect to the proposal to liquidate the Fund. As noted, copies of the Fund’s proxy statement will also be mailed to each stockholder of record of the Fund. Upon receipt, stockholders are advised to read the Fund’s proxy statement as it will contain important information. Once filed with the SEC, the proxy statement will be available free of charge on the SEC website, www.sec.gov.

This press release may contain statements regarding plans and expectations for the future that constitute forward-looking statements within the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the Fund’s current plans and expectations, and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Additional information concerning such risks and uncertainties are contained in the Fund’s regulatory filings, which are available free of charge on the SEC’s website. An investment in the Fund involves risk, including loss of principal. Investment return and the value of shares will fluctuate. Any data and commentary provided in this press release are for informational purposes only.

The Fund is a closed-end management investment company. The Fund’s investment manager is Matthews International Capital Management, LLC. For further information regarding the Fund, please call (888)-CHN-CALL or visit the Fund’s website at www.chinafundinc.com. The information contained on the Fund’s website is not part of this press release. Copies of the Fund’s complete audited financial statements are available free of charge upon request.

Investments involve risk, including possible loss of principal, and an investment should be made with an understanding of the risks involved with owning a particular security or asset class. Interested parties are strongly encouraged to seek advice from qualified tax and financial experts regarding the best options for your particular circumstances.

Contact

Julian Reid
Chairman of the Board
The China Fund, Inc.
+44 7768 068200



Posted on

DDB Worldwide Named Cannes Lions 2025 Network of the Year for the Second Time in Two Years

PR Newswire

Omnicom Network Achieves Record Number of Wins in 76-Year History Under Recently Appointed Global Leadership


CANNES, France
, June 20, 2025 /PRNewswire/ — DDB Worldwide, part of Omnicom, has once again claimed the prestigious title of Network of the Year at the 2025 Cannes Lions International Festival of Creativity. This marks the second time the network has secured the honor, following its historic first win in 2023. In a record-breaking year, DDB surpassed its 2023 award tally with a total of 112 Lions, further cementing its place at the forefront of the global creative industry.

DDB’s continued rise comes just one year into the leadership of Global CEO Alex Lubar and President & Global Chief Creative Officer, Chaka Sobhani. Since taking the reins, the duo has steered the network into a new era; one defined by tighter integration, emotionally-led creativity, and a sharpened focus on work that delivers both cultural impact and real business results.

Chaka Sobhani commented: “I literally don’t have the words. This means the absolute world to us. I couldn’t be prouder of our DDB network and the passion, commitment, and love that has gone behind us getting here. A huge thank you also to our amazing clients for their trust and partnership – we wouldn’t be here without you and I hope we’ve made you proud. Hopefully, this is the start of much more to come from DDB – and on a personal note, I can only say it’s been the most incredible first year!”

“2023 was a landmark year for DDB, but we saw it as the beginning,” said Alex Lubar. “The momentum you’re seeing now is the result of a global network aligned around a simple belief: creativity is the most powerful force in business. I’m incredibly proud of our exceptional teams and client partners on this collective effort.”

2025 Cannes Lions highlights:

  • Regional Network of the Year – Latin America
  • Regional Network of the Year – Pacific
  • Classic Track Agency of the Year – Africa Creative DDB
  • Good Track Agency of the Year – Africa Creative DDB
  • Experience Track Agency of the Year – DM9
  • Africa Creative DDB is the 1st ranked agency in Brazil, 2nd in Agency of the Year
  • The first time DDB won four Grands Prix across different brands since 2016, including:
    • Audio & Radio: “One Second Ads” (Budweiser, Africa Creative DDB)
    • Music: “Tracking Bad Bunny” (Rimas Entertainment, DDB Latina Puerto Rico)
    • Creative Data: “Efficient Way to Pay” (Consul, DM9)
    • Sustainable Development Goals: “The Amazon Greenventory” (Natura, Africa Creative DDB)
  • 20 total Gold Lions
  • 37 total Silver Lions
  • 51 total Bronze Lions
  • 320 total shortlists
  • First Gold Cannes Lion in Finland for Nordea, Parental Leave Mortgage
  • First Grand Prix for DDB Latina Puerto Rico, and Puerto Rico’s second in history
  • First Gold for DDB Warsaw for McDonald’s Winter Takes on Color in Brand Experience & Activation
  • Most Lions and Grands Prix won by DDB Latina ever, with 78 trophies vs their previous record of 44
  • Most awarded network in Brand Experience & Activation with 20 trophies
  • Most awards on behalf of McDonald’s than any other agency network

This creative surge has been powered by the DDB Global Creative Council, Bullseye, which is led by Global Chief Creative Operations Officer, Susie Walker, and continues to push boundaries across regions. This year, the program has been expanded to include rising creative talent, who have actively shaped DDB’s award-winning creative work.

DDB’s rise has also been fueled by the growing influence of some of its most dynamic agencies, including DDB Paris, Africa Creative DDB, alma, DM9, and NORD DDB, whose bold, culturally resonant work continues to redefine the standard of global creative excellence.

As creativity becomes an increasingly vital business differentiator, DDB’s Cannes success proves its belief that emotional storytelling not only moves people, it moves markets. This year’s winning campaigns have not only earned accolades but delivered measurable growth for clients across categories.

ABOUT DDB WORLDWIDE

DDB (www.ddb.com) is The Emotional Advantage Agency.

We believe when people feel, they act—and when they act, brands grow. That’s the emotional advantage. We use it to deliver intimacy at scale, unlock brand growth, and craft ideas that move people, business, and culture forward.

As one of the world’s leading advertising and marketing networks, DDB blends creative excellence with strategic effectiveness to drive measurable results. With 140 offices in 60+ countries, we partner with iconic brands like MARS, McDonald’s, Molson Coors, Volkswagen, Amazon, Unilever, JetBlue, Adidas, PlayStation, and the U.S. Army.

Our impact is proven: we were named the #1 Most Awarded Agency Network in the 2024 Effie Global Best of the Best, Global Network of the Year by Cannes Lions (2023 and 2025), and D&AD Network of the Year for three consecutive years (2021–2023). We’ve also ranked as a Top 3 Global Network on WARC for 13 of the last 16 years.

Founded in 1949, DDB is part of Omnicom (NYSE: OMC).

Media Contact

[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ddb-worldwide-named-cannes-lions-2025-network-of-the-year-for-the-second-time-in-two-years-302487545.html

SOURCE DDB Worldwide

Posted on

INVESTOR ALERT: Apple Inc. Investors with Substantial Losses Have Opportunity to Lead the Apple Class Action Lawsuit – AAPL

PR Newswire


SAN DIEGO
, June 20, 2025 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Apple Inc. (NASDAQ: AAPL) securities between June 10, 2024 and June 9, 2025, inclusive (the “Class Period”), have until August 19, 2025 to seek appointment as lead plaintiff of the Apple class action lawsuit. Captioned Tucker v. Apple Inc., No. 25-cv-05197 (N.D. Cal.), the Apple class action lawsuit charges Apple and certain of Apple’s top current and former executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Apple class action lawsuit, please provide your information here:


https://www.rgrdlaw.com/cases-apple-inc-class-action-lawsuit-aapl.html
 

You can also contact attorneys

J.C. Sanchez

or


Jennifer N. Caringal


of Robbins Geller by calling 800/449-4900 or via e-mail at

[email protected]

.

CASE ALLEGATIONS: The Apple class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Apple misstated the time it would take to integrate the advanced artificial intelligence (“AI”)-based Siri features into its devices; (ii) accordingly, it was highly unlikely that these features would be available for the iPhone 16; (iii) the lack of such advanced AI-based features would hurt iPhone 16 sales; and (iv) as a result, Apple’s business and/or financial prospects were overstated.

The Apple class action lawsuit further alleges that on March 7, 2025, Apple announced it was indefinitely delaying promised updates to its Siri digital assistant. The Apple class action lawsuit alleges that on this news, the price of Apple stock fell.

Then, on March 12, 2025, the Apple class action lawsuit further alleges that Morgan Stanley published a report in which analyst Erik Woodring lowered his price target on Apple from $275 to $252, asserting that the delay in introducing advanced Siri features would impact iPhone upgrade cycles throughout 2025 and 2026, and presenting evidence that roughly 50% of iPhone owners who did not upgrade to the iPhone 16 attributed their decision to such delays. On this news, the price of Apple stock fell further, according to the complaint.

Thereafter, the Apple class action lawsuit alleges that on April 3, 2025, the Wall Street Journal published an article titled “Apple and Amazon Promised Us Revolutionary AI. We’re Still Waiting,” which stated, in relevant part, that “[w]ith ‘more personal’ Siri . . . , the tech giant[] marketed features [it] ha[s] yet to deliver,” and suggested that while “this is challenging technology and the cost of getting it wrong is devastatingly high, especially for [a] compan[y] like Apple . . . that must build trust with customers,” “the same responsibility applies to marketing: They shouldn’t announce products until they’re sure they can deliver them.” On this news, the price of Apple stock fell more than 7%, according to the complaint.

Finally, on June 9, 2025, Apple hosted its Worldwide Developer Conference (“WWDC”), almost one year to the day after first announcing the suite of supposedly forthcoming Apple Intelligence features at the 2024 WWDC, and Apple failed to announce any new updates regarding advanced Siri features, according to the complaint. On this news, the price of Apple stock fell further, according to the complaint.

Last year, Robbins Geller secured a $490 million recovery in a securities fraud class action case alleging Apple CEO Timothy Cook made false and misleading statements to investors – the third-largest securities class action recovery ever in the Northern District of California and the fifth-largest such recovery ever in the Ninth Circuit. In the order granting final approval of the settlement, the court recognized the “skill and strategic vision, as well as the risk taken by [Robbins Geller]” in securing the sizeable recovery while efficiently managing the “uniquely complex” aspects of the case against “highly sophisticated and experienced counsel and defendants.” Learn more by clicking here. 

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Apple securities during the Class Period to seek appointment as lead plaintiff in the Apple class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Apple class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Apple class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Apple class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices. 

Contact:
            Robbins Geller Rudman & Dowd LLP
            J.C. Sanchez, Jennifer N. Caringal
            655 W. Broadway, Suite 1900, San Diego, CA 92101
            800-449-4900
            [email protected] 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-apple-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-apple-class-action-lawsuit—aapl-302487482.html

SOURCE Robbins Geller Rudman & Dowd LLP

Posted on

enCore Energy Announces Filing of Early Warning Report

PR Newswire

NASDAQ:EU

TSXV:EU


www.encoreuranium.com
 


DALLAS
, June 20, 2025 /PRNewswire/ – enCore Energy Corp. (NASDAQ: EU) (TSXV: EU) (the “Company” or “enCore”), America’s Clean Energy Company™, announces that it has disposed of 170,000,000 common shares in the capital of Anfield Energy Inc. (“Anfield“) (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) in a private agreement at a price of $0.115 per share for aggregate proceeds of $19,550,000 (Canadian dollars).

Immediately following the disposition, enCore holds or controls no common shares of Anfield. The disposition represents a 14.73% decrease in enCore’s ownership or control over the outstanding common shares of Anfield on an undiluted basis. enCore does not currently hold or control any securities of Anfield.

Since enCore’s last early warning report dated January 15, 2024, enCore’s holdings have decreased by an approximate 16.02% of the outstanding common shares of Anfield on an undiluted basis.

enCore disposed of the shares of Anfield in a private transaction. enCore may, depending on market and other conditions, increase beneficial ownership of the Company’s securities, whether in the open market, by privately negotiated agreements or otherwise, subject to a number of factors, including general market conditions and other available investment and business opportunities.

The disclosure respecting enCore’s shareholdings contained in this news release is made pursuant to National Instrument 62-103 and a report respecting the above disposition will be filed with the applicable securities commissions and will be available for viewing at www.sedarplus.ca. A copy of the report may also be obtained by contacting Robert Willette, Acting Chief Executive Officer, or at [email protected].

About enCore Energy Corp.
enCore Energy Corp., America’s Clean Energy Company™, is committed to providing clean, reliable, and affordable fuel for nuclear energy as the only United States uranium company with multiple central processing plants in operation. enCore operates the 100% owned and operated Rosita CPP in South Texas and the 70/30 joint venture Alta Mesa CPP with Boss Energy Ltd., with enCore operating as the project manager.

The enCore team is led by industry experts with extensive knowledge and experience in all aspects of ISR uranium operations and the nuclear fuel cycle. enCore solely utilizes ISR for uranium extraction, a well-known and proven technology co-developed by the leaders at enCore Energy. Following upon enCore’s demonstrated success in South Texas, future projects in enCore’s planned project pipeline include the Dewey-Burdock project in South Dakota and the Gas Hills project in Wyoming. The Company holds other assets including non-core assets and proprietary databases. enCore is committed to working with local communities and indigenous governments to create positive impact from corporate developments.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/encore-energy-announces-filing-of-early-warning-report-302487517.html

SOURCE enCore Energy Corp.

Posted on

New Research on Abbott’s Healthy Food Rx Program Shows ‘Food is Medicine’ Approach Helps People Living With Diabetes Eat Better and Feel Healthier

PR Newswire

  • Randomized, controlled clinical trial presented as a late-breaking poster at ADA’s Scientific Sessions shows people participating in Abbott’s Healthy Food Rx ate more vegetables and fruit, and reported significantly improved health status.
  • Abbott’s Healthy Food Rx community-focused “food is medicine” program provides home-delivered healthy food boxes and nutrition education in Stockton, Calif., where 60% of the population has diabetes or pre-diabetes.


CHICAGO
, June 20, 2025 /PRNewswire/ — Late-breaking research presented at the American Diabetes Association’s 85th Scientific Sessions showed that Abbott’s (NYSE: ABT) Healthy Food Rx “food is medicine” program helped people living with diabetes to eat better and feel healthier, with participants reporting improved diet quality and health status.

This study is one of the few randomized controlled clinical trials examining the impact of food is medicine programs. Conducted by the Public Health Institute Center for Wellness and Nutrition (PHI CWN), this clinical trial assessed the impact of Abbott’s Healthy Food Rx in a highly food insecure, low-income, community-based setting of 364 people living with diabetes over a six-month period. The Healthy Food Rx program provides home-delivered, meal-based healthy food boxes accompanied by nutrition education to help address diabetes.

Key study results include:

  • Improved diet quality: Healthy Food Rx participants reported significantly increased vegetable consumption compared to the control group (0.37 vs. 0.03 increased servings per day; p = 0.007), and increased fruit consumption compared to control group (0.3 vs. 0.2 increased servings per day, p = 0.232).
  • Improved health status: Healthy Food Rx participants reported significantly greater improvements in self-reported physical health status over six months (from 38% to 63%, p < 0.001), compared to the control group (from 47% to 50%, p=0.453; between group p<0.001).
  • Lowered A1C levels in both groups: A1C levels significantly improved for both Healthy Food Rx participants and the control group. A1C is a test that reflects average glucose levels for the past three months; levels decreased by 0.7% and 1.2%, in the intervention group and control group, respectively. Both values exceeded the widely accepted 0.5% benchmark that is considered a clinically significant change and is associated with improved health outcomes in people with diabetes.
  • Participants were strongly satisfied with Healthy Food Rx, and shared with family and friends. Participants in Abbott’s Healthy Food Rx reported strong satisfaction – 98% were satisfied with the program and 97% used all or most of the food. Two-thirds of participants (67%) shared the food with two or more people, and 99% were likely to recommend the program to others.

“Living with diabetes in an economically underserved community can present numerous challenges, from limited access to affordable, healthy foods to a lack of appropriate health services,” said Erika Takada, Executive Director, Public Health Institute Center for Wellness and Nutrition. “Even with a program that reaches participants just twice a month, we are seeing benefits in people with diabetes eating better foods and feeling healthier. This underscores the foundational role that good nutrition can play in helping to address the impact of diabetes and other chronic diseases on our families and communities.”

Launched in 2021, Abbott’s Healthy Food Rx is one of the largest community-focused food is medicine programs in the country, reaching more than 1,700 participants to date. These clinical trial findings build on results of an earlier 12-month study that showed clinically important benefits among Healthy Food Rx participants living with diabetes.

“Programs like Abbott’s Healthy Food Rx are critically important in communities like Stockton where diabetes incidence and risk are significantly higher,” said Kwabena O. Adubofour, MD, FACP, Internal Medicine Specialist and a Board Certified Diabetologist at Community Medical Centers (CMC) in Stockton. “From results like A1C reduction to even personal well-being, participants from the CMC clinic benefited greatly from access to healthy foods and nutrition resources. It will be important to see how these benefits translate into long-term improvements in diabetes outcomes so people can lead healthier, fuller lives.”

“We’re pleased that results from Abbott’s Healthy Food Rx can contribute to a better understanding of the impacts that programs like this can have for people living with diabetes,” said Melissa Brotz, president of Abbott Fund and senior vice president of Global Marketing and External Affairs at Abbott. “By integrating healthy food and nutrition education as part of a broader effort to remove barriers to care, we’re helping people to feel more in control and take an active role in managing their health.”

About the Clinical Trial
A delayed intervention randomized clinical trial design was used. Participants were recruited by health educators and randomized into two groups: the intervention group received home-delivered, meal-based food boxes once every other week for six months with nutrition education in the form of recipes, cooking videos and text messages; the control group received the intervention after the six-month study period. All participants received usual care, including potential medication prescriptions and optional diabetes education and social needs referrals.

Participants were administered surveys at enrollment and after six months, with hemoglobin A1C assessed as the primary outcome, and secondary outcomes including fruit and vegetable intake, food security and health status. Study results can be found here.

About Abbott’s Healthy Food Rx
Abbott’s Healthy Food Rx program is part of the company’s Future Well™Communities initiative, a multi-year effort to advance health access by removing the barriers that prevent people with diabetes from living healthy lives.

Abbott partnered with PHI CWN to design and implement Healthy Food Rx with Stockton-based organizations, with funding support from Abbott’s foundation, Abbott Fund. CMC, a local federally qualified health center in Stockton, identified potential Healthy Food Rx participants. Program participants received food boxes from the Emergency Food Bank Stockton/San Joaquin (EFB), delivered directly to their home every other week for six months. The boxes included ingredients for a family-sized healthy meal with lean protein, vegetables and fruits, as well as pantry staples such as beans, rice and nuts. The box also contained a recipe card and link to an optional online cooking class with EFB, which provided additional guidance and diabetes education.

About the Public Health Institute and the Center for Wellness and Nutrition
The Public Health Institute, an independent nonprofit organization, advances wellbeing and health equity with communities around the world. PHI develops research, leadership and partnerships to build strong public health policy, programs, systems and practices. For more information, visit phi.org. The Center for Wellness and Nutrition (CWN, centerforwellnessandnutrition.org), a program of the Public Health Institute, is a national leader in developing campaigns, programs and partnerships to promote wellness and equitable practices in the most vulnerable communities in California and across the country.

About Abbott and Abbott Fund
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

Abbott Fund is a philanthropic foundation established by Abbott in 1951. Abbott Fund’s mission is to create healthier global communities by investing in creative ideas that promote science, expand access to healthcare and strengthen communities worldwide. For more information on Abbott Fund, visit www.abbottfund.org.

Cision View original content:https://www.prnewswire.com/news-releases/new-research-on-abbotts-healthy-food-rx-program-shows-food-is-medicine-approach-helps-people-living-with-diabetes-eat-better-and-feel-healthier-302487489.html

SOURCE Abbott

Posted on

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.

“The amylin receptor is rapidly gaining clinical validation as a key target in obesity, driven by encouraging data from injectable peptide programs. We believe ACCG-2671 is well-positioned and differentiated as an oral small molecule frontrunner that is expected to enter clinical development by the end of 2025,” said Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics. “The preclinical data being presented at ADA include the robust weight-loss effects of ACCG-2671 alone and in combination with a GLP-1 receptor agonist underscoring ACCG-2671’s potential as a future small molecule backbone treatment for obesity. In addition, we will present data demonstrating the neuroprotective effects of GLP-1 receptor agonism in preclinical models of Parkinson’s disease, reinforcing the broad role of the GLP-1 receptor across different diseases.”

Presentation Details:

Title: Novel Oral Small Molecule ACCG-2671: A Dual Amylin and Calcitonin Receptor Agonist Development Candidate for Obesity Therapy
Poster #: 2184-LB
Session: Late Breaking Poster Session
Date: Sunday, June 22
Time: 12:30 p.m. – 1:30 p.m. CT
Summary: ACCG-2671 demonstrated high binding affinity and balanced potency in human calcitonin receptor (CTR) and amylin receptor (AMY3R) functional assays. In diet-induced obese rats, oral administration of ACCG-2671 resulted in significant, dose-dependent body weight reductions. Combination therapy with semaglutide (both as add-on and concurrent treatment) resulted in superior weight loss compared to monotherapy.

Title: Oral Small Molecule GLP-1 Receptor Agonist Demonstrates Beneficial Effects in Parkinson’s Disease–Like Model Using Humanized GLP-1R Mice
Poster #: 1985-LB
Session: Late Breaking Poster Session
Date: Sunday, June 22
Time: 12:30 p.m. – 1:30 p.m. CT
Summary: In a Parkinson’s disease mouse model, oral administration of GSBR-5595, a small molecule GLP-1 receptor agonist distinct from Structure Therapeutics’ clinical asset aleniglipron (GSBR-1290), significantly improved motor coordination and movement in both the rotarod and open field tests. Additionally, histopathological analyses revealed a significant increase in dopaminergic neurons. These findings suggest this GLP-1 receptor agonist showed neuroprotective effects by mitigating motor deficits and preserving dopaminergic neurons, highlighting a potential benefit in Parkinson’s disease.

About Structure Therapeutics

Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company’s future plans and prospects; the belief that ACCG-2671 is well-positioned and differentiated as an oral small molecule frontrunner; the planned initiation of the ACCG-2671 Phase 1 study and the timing thereof; the belief that the oral small molecule approach gives Structure Therapeutics the opportunity to create more scalable, cost-effective treatments to meet the needs of patients with obesity and other related diseases, without compromising on efficacy or safety; the belief that Structure Therapeutics is well-positioned with one of the most robust oral small molecule metabolic franchises in the industry; and any expectations regarding the safety, efficacy or tolerability of ACCG-2671and other candidates under development. In addition, when or if used in this press release, the words and phrases “anticipated,” “expect,” “on track,” “plan,” “potential,” “to be,” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to the results from earlier clinical studies not necessarily being predictive of future results, potential delays in the commencement, enrollment and completion of the Company’s planned clinical studies, the Company’s ability to advance ACCG-2671 and its other therapeutic candidates, obtain regulatory approval of and ultimately commercialize the Company’s therapeutic candidates, competitive products or approaches limiting the commercial value of the Company’s product candidates, the timing and results of preclinical and clinical studies, the Company’s ability to fund development activities and achieve development goals, the Company’s reliance on third parties, including clinical research organizations, manufacturers, suppliers and collaborators, over which it may not always have full control, the impact of any global pandemics, inflation, tariffs, changes in monetary and fiscal policy, supply chain issues, rising interest rates, future bank failures and other macroeconomic factors on the Company’s business, its ability to protect its intellectual property and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investors:

Danielle Keatley
Structure Therapeutics Inc.
[email protected]

Media:

Dan Budwick
1AB
[email protected]



Posted on

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

– Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit –

– All 12 patients with at least one year of follow-up who received a full dose of zimislecel as a single infusion achieved ADA-recommended target HbA1c levels <7% and >70% time-in-range (70-180 mg/dL), and 10/12 patients were insulin free –

–Data presented at ADA simultaneously published in the New England Journal of Medicine –

– Vertex to host investor webcast tonight, June 20, 2025, at 7:15 p.m. CT / 8:15 p.m. ET –

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American Diabetes Association (ADA) annual conference in Chicago as part of the symposium, “Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy,” from 6:15-6:30 p.m. CT (abstract 2025-A-1921) and published online by the New England Journal of Medicine.

The data are from 12 patients who received the full dose of zimislecel as a single infusion and were followed for at least one year, as of October 2024. Results from the study to date continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit with longer follow-up. All12 participants:

  • Demonstrated engraftment with glucose-responsive endogenous C-peptide production, which was durable through one year of follow-up.

  • Achieved the ADA targets of HbA1c <7% and time in range of >70%.

  • Were free of SHEs from day 90 onwards.

  • Had a reduction in exogenous insulin use (mean reduction in daily insulin dose: 92%).

    • 10/12 (83%) no longer required exogenous insulin at Month 12.

  • Achieved the Phase 1/2 primary endpoint of elimination of SHEs with HbA1c <7%.

Zimislecel continues to be generally well tolerated. Most adverse events (AEs) were mild or moderate, and there were no serious AEs related to zimislecel treatment. As previously reported, two patient deaths occurred, both unrelated to treatment with zimislecel. The safety profile is generally consistent with the immunosuppressive regimen used in the study, the infusion procedure, and complications from long-standing diabetes.

“These data on the first fully differentiated, stem cell-derived, off-the-shelf islet cell therapy continue to be unprecedented. The magnitude, consistency and durability of the results from all 12 patients with more than one year of follow-up reinforce the transformative potential of zimislecel for people living with T1D complicated by severe hypoglycemia,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. “We are excited to complete enrollment and dosing in the Phase 1/2/3 Program and look forward to potential regulatory submissions next year.”

“It’s remarkable to see 12 out of 12 patients with baseline HbA1c above 7% and multiple severe hypoglycemic events reach consensus targets for glycemic control by both HbA1c and time in range as well as elimination of severe hypoglycemic events,” said Michael R. Rickels, M.D., M.S., Medical Director, Pancreatic Islet Cell Transplant Program, Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, Presenting Author and Steering Committee Co-Chair for the zimislecel clinical program, and author on the New England Journal of Medicine paper. “As I think about my patients and the unmet need in the type 1 diabetes community, the results we’ve seen so far for restoring endogenous insulin secretion with a stem cell-derived islet therapy bring me hope and confidence for a transformative treatment option for individuals with type 1 diabetes in the not-so-distant future.”

About Type 1 Diabetes

T1D results from the autoimmune destruction of insulin-producing beta cells in pancreatic islets. Insulin deficiency results in hyperglycemia and can lead to acute life-threatening complications such as diabetic ketoacidosis.

People with T1D are reliant on lifelong treatment with exogenous insulin that requires careful monitoring of blood glucose levels. Even with the availability of advanced exogenous insulin delivery and glucose monitoring systems, people with T1D can have periods of very low and very high blood sugar levels. Exogenous insulin has a narrow therapeutic range and carries an inherent risk of causing low blood sugar levels or hypoglycemic events, which can potentially result in arrhythmias, seizures, coma and even death. Due to the limitations and complexities of exogenous insulin treatment, it can be difficult for people with T1D to achieve and maintain good glucose control. Exposure to prolonged periods of high blood glucose levels, or hyperglycemia, can lead to long-term complications such as nerve damage, kidney disease/failure, eye disease (including vision loss), cardiovascular disease, stroke and even death.

HbA1c is a measure of average blood glucose over the most recent ~2-3 months, and the consensus guidance is to maintain an HbA1c of <7% to reduce the risk of long-term complications; only ~1 in 4 people with T1D globally meet this clinical target. Current standards of care do not address the underlying cause of the disease and leave people with T1D susceptible to both hypo- and hyperglycemia and their associated morbidity and mortality. There is no cure for T1D.

About Zimislecel

Zimislecel (VX-880) is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. Zimislecel is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. Zimislecel has the potential to restore the body’s ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. Zimislecel is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. The zimislecel trial has expanded to additional sites that are currently active and enrolling in the U.S., Canada and Europe.

Zimislecel has been granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration, Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and has secured an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Zimislecel is investigational and has not been approved by health authorities globally.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry’s top places to work, including 15 consecutive years on Science magazine’s Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex’s history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, (i) statements by Carmen Bozic, M.D., and Michael R. Rickels, M.D., M.S., in this press release, (ii) plans, expectations for, and the potential benefits of zimislecel, (iii) expectations for the Phase 1/2/3 clinical trial for zimislecel, including expectations for the trial to complete enrollment and dosing, and (iv) plans for potential regulatory submissions next year. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company’s beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company’s research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, that timelines for regulatory submissions may be longer than anticipated, and other risks listed under the heading “Risk Factors” in Vertex’s most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at www.sec.gov and available through the company’s website at www.vrtx.com. You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

Investor Event and Webcast

Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section of Vertex’s website at https://investors.vrtx.com/. An archived webcast will be available on the company’s website.

Vertex Pharmaceuticals Incorporated


Investors:

[email protected]

Media:

[email protected]

or

International: +44 20 3204 5275

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Science Stem Cells Biotechnology Research Pharmaceutical Health Diabetes Clinical Trials

MEDIA:

Logo
Logo
Posted on

B2Gold Announces Voting Results from its 2025 Annual General and Special Meeting

VANCOUVER, British Columbia, June 20, 2025 (GLOBE NEWSWIRE) — B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on Thursday, June 19, 2025. A total of 864,407,409 common shares were voted at the Meeting, representing 65.42% of the votes attached to all outstanding common shares.

Shareholders voted overwhelmingly in favour of all items of business before the Meeting. The ten director nominees listed in B2Gold’s Management Information Circular (the “Circular”) dated May 2, 2025, were elected as directors of B2Gold to hold office for the ensuing year or until their successors are elected or appointed. Detailed results of the vote for each director are set out below:

Name Total Votes in Favour Total Votes Withheld
Gregory Barnes 791,120,148 5,186,604
Kevin Bullock 787,025,110 9,281,643
Kelvin Dushnisky 606,644,165 189,662,587
Clive Johnson 755,333,955 40,972,797
Liane Kelly 789,718,983 6,587,770
Jerry Korpan 785,018,977 11,287,775
Thabile Makgala 792,134,499 4,172,253
Basie Maree 792,048,992 4,257,760
Lisa Pankratz 789,377,863 6,928,890
Robin Weisman 780,638,556 15,668,197

The resolutions to appoint PricewaterhouseCoopers LLP as auditor of the Company was approved with 96.60% of votes cast in favour.

The resolution regarding the Advisory Vote on the Company’s approach to Executive Compensation was approved with 93.23% of votes cast in favour.

A report on all items of business voted on at the Meeting has been filed on Sedar+ at www.sedarplus.com.

About B2Gold

B2Gold is a responsible international senior gold producer headquartered in Vancouver, Canada. Founded in 2007, today, B2Gold has operating gold mines in Mali, Namibia and the Philippines, the Goose Project under construction in northern Canada and numerous development and exploration projects in various countries including Mali, Colombia and Finland.

ON BEHALF OF B2GOLD CORP.

“Clive T. Johnson”
President & Chief Executive Officer

The Toronto Stock Exchange and NYSE American LLC neither approve nor disapprove the information contained in this news release.

Source: B2Gold Corp.



For more information on B2Gold please visit the Company website at www.b2gold.com or contact:

Michael McDonald
VP, Investor Relations & Corporate Development
+1 604-681-8371
[email protected]

Cherry DeGeer
Director, Corporate Communications
+1 604-681-8371
[email protected]  

Posted on

DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Aflac Incorporated Customers Whose Data May Have Been Compromised

NEWTOWN, Pa., June 20, 2025 (GLOBE NEWSWIRE) — The law firm of Edelson Lechtzin LLP is investigating data privacy claims regarding an incident at Aflac Incorporated (“Aflac”). Aflac learned of suspicious activity on its network or about June 12, 2025.

About Aflac Incorporated

Aflac, a Fortune 500 company, is known for its specialized insurance products that help cover expenses that health insurance may not. Originally established as the American Family Life Assurance Company of Columbus, it officially shortened its name to Aflac in 1989.

What happened?

On or around June 12, 2025, Aflac discovered suspicious activity on its network. They immediately launched an investigation and have since determined that this breach was caused by a group of cybercriminals, who potentially gained access to personal information.

What type of information was stolen?

The personal information in the compromised files may have included:

  • Names
  • Health Information
  • Social Security Numbers
  • Other Information Related to Customers, Beneficiaries, Employees, Agents, and other individuals

How can I protect my personal data?

If you receive a data breach notification concerning Aflac, you must guard against identity theft and fraud by regularly reviewing your account statements and monitoring your credit reports for suspicious or unauthorized activity.

Edelson Lechtzin LLP is investigating a class action lawsuit to seek legal remedies for individuals whose sensitive personal data may have been compromised by the Aflac data breach.

For more information, please contact:

Marc H. Edelson, Esq.
EDELSON LECHTZIN LLP
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492 ext. 2
Email: [email protected]
Web: www.edelson-law.com

About Edelson Lechtzin LLP

Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving data breaches, our lawyers focus on class and collective litigation in cases alleging securities and investment fraud, violations of the federal antitrust laws, employee benefit plans under ERISA, wage theft and unpaid overtime, consumer fraud, and catastrophic injuries.

This press release may be considered Attorney Advertising in some jurisdictions.